Company intelligence / Profile preview

Alopexx, Inc.

Cambridge, Massachusetts, United Statesalopexx.com ↗

Ownership: Public · ALPX
Development stage: Phase 2

Overview

AV0328 vaccine has completed Phase 1 trials showing it induces protective antibodies against PNAG-expressing pathogens. F598 monoclonal antibody has completed Phase 1 and pilot Phase 2 trials with no serious adverse events, providing 2-3 months of protection after a single infusion.

Therapeutic areas: Infectious Diseases
Modalities: VaccinesMonoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

F598

1 more asset in the full pipeline.

Request access →

Partnerships

Bharat BiotechBiotech Consortia Inc.

Financials

Market cap: $118.6M
Enterprise value: $118.6M

Beyond the preview

Go deeper on Alopexx, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alopexx, Inc..

Explore the full profile